A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of Ibrutinib in Combination with Rituximab vs Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma(PERSPECTIVE)
A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of Ibrutinib in Combination with Rituximab vs Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma(PERSPECTIVE)
Trial Category:
Lymphoma
Phase
III
Contact(s)
Location(s)
Southeast Nebraska Cancer Center, Lincoln, NE
This study is evaluating the use of Ibrutinib with Rituxan for follicular lymphoma patients who have not been previously treated. This study is "double blind" meaning neither the patient or clinical team will know whether the Ibrutinib is being administered. The patient will receive either Ibrutinib or a placebo( a pill that looks like ibrutinib but has no medical effect). The purpose of this type of study is to clearly evaluate the benefit of the drug using the same criteria for both treatments,
